An extracellular vesicle-mediated mitochondrial transfer network critical for testosterone synthesis
Brief intro:
- Author: Kai Xia, Suyuan Zhang, Hao Peng, Hainan Chen, Cuifeng Yang, Jiajie Yu, Peng Luo, Qiying Lu, Hong Chen, Li Huang, Yifei Xiong, Lerong Zhao, Lei Jia, Lu Li, Yuan Qiu, Yan Guo, Congyuan Liu, Hang Fan, Ziran Dai, Guihua Liu, Qiong Ke, Tao Wang, Weiqiang Li, Lili Chen, Chunhua Deng, Haipeng Xiao & Andy Peng Xiang
- Journal: Nature Cell Biology
- Doi: https://www.doi.org/10.1038/s41556-026-01896-x
- Publication Date: 2026/2/27
Abstract
Testosterone production by testicular Leydig cells (LCs) in male mammals is energetically demanding and prone to mitochondrial damage. Despite these challenges, LCs exhibit remarkable longevity and minimal turnover, suggesting the existence of specialized mechanisms that maintain LC mitochondrial homeostasis under such constrains. Here we identify a mitochondrial transfer network between LCs and different testicular macrophage (tMac) subpopulations. Leydig cells release extracellular vesicles containing defective mitochondria, which are eliminated by CD206hi tMacs in a TREM2-dependent process. Deletion of Trem2 in tMacs disrupts this transfer, leading to impaired testosterone synthesis. Conversely, LCs acquire extracellular vesicles containing functional mitochondria from MHCIIhi tMacs through ITGβ1–VCAM1 interactions. Loss of Vcam1 in LCs hinders this mitochondrial transfer, thereby compromising testosterone production. Together, our findings reveal an unrecognized mitochondrial transfer network between LCs and tMacs that safeguards LC homeostasis and testosterone production, offering valuable insights into intercellular communication mechanisms that maintain tissue homeostasis.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.